Steroid resistance in inflammatory bowel disease

Cover Page


Cite item

Full Text

Abstract

Systemic glucocorticosteroids are widely used in the treatment of inflammatory bowel disease, and despite the introduction of new anti-inflammatory drugs, remain the first-line therapy for induction of remission in moderate and severe ulcerative colitis and Crohn's disease. However, in some patients steroid resistance is observed when glucocorticosteroids are not effective enough. The paper gives a detailed discussion of the criteria of steroid resistance, possible mechanisms of it's development, including secondary resistance resulting from complications of ulcerative colitis and Crohn's disease and associated opportunistic infections. Special attention is paid to the modern treatment of steroid-refractory inflammatory bowel disease.

About the authors

A. G. Kharitonov

North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg

Author for correspondence.
Email: mldruz@gmail.com

Kharitonov Andrey G. – MD, PhD, Associate Professor, Chair of Internal Diseases Propedeutics, Gastroenterology and Nutrition.

41 Kirochnaya ul., Saint Petersburg, 191015, Russian Federation. Tel.: +7 (812) 235 10 93. E-mail: mldruz@gmail.com

Russian Federation

O. B. Shchukina

North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg

Email: fake@neicon.ru
Shchukina Oksana B. – MD, PhD, Associate Professor, Chair of Internal Diseases Propedeutics, Gastroenterology and Nutrition Russian Federation

E. A. Kondrashina

North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg

Email: fake@neicon.ru
Kondrashina Elina A. – MD, PhD, Associate Professor, Chair of Internal Diseases Propedeutics, Gastroenterology and Nutrition Russian Federation

References

  1. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006;12(38):6102-8. doi: 10.3748/WJG.v12.i38.6102.
  2. Trallori G, Palli D, Saieva C, Bardazzi G, Bonano-mi AG, d'Albasio G, Galli M, Vannozzi G, Milla M, Tarantino O, Renai F, Messori A, Amorosi A, Pacini F, Morettini A. A population-based study of inflammatory bowel disease in Florence over 15 years (1978-92). Scand J Gastroenterol. 1996;31(9):892-9.
  3. Dignass A, Eliakim R, Magro F, Maaser C, Chow-ers Y, Geboes K, Mantzaris G, Reinisch W, Co-lombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6(10):965-90. doi: 10.1016/j.crohns.2012.09.003.
  4. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkuhn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris G, Travis S, Stange E; European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis. 2010;4(1):7-27. doi: 10.1016/j.crohns.2009.12.003.
  5. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zins-meister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gas-troenterology. 2001;121(2):255-60. doi: http://dx.doi.org/10.1053/gast.2001.26279.
  6. Yoon JY, Cheon JH, Park JJ, Hong SP, Kim TI, Kim WH. Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. J Gastroenterol Hepatol. 2011;26(7):1114-22. doi: 10.1111/j.1440-1746.2011.06688.x.
  7. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35(3):360-2.
  8. Schimmer B, Parker K. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's The pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006. p. 901-13.
  9. Escriva H, Delaunay F, Laudet V. Ligand binding and nuclear receptor evolution. Bioessays. 2000;22(8):717-27. doi: 10.1002/1521-1878(200008)22:8<717::AID-BIES5>3.0.CO;2-I.
  10. De Iudicibus S, Franca R, Martelossi S, Ventura A, Decorti G. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol. 2011;17(9):1095-108. doi: 10.3748/wjg.v17.i9.1095.
  11. Dignass A, Lindsay JO, Sturm A, Windsor A, Co-lombel JF, Allez M, D'Haens G, D'Hoore A, Man-tzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Ass-che G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991-1030. doi: 10.1016/j.crohns.2012.09.002.
  12. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollon F, Hommes DW, Michetti P, O'Morain C, Oresland T, Windsor A, Stange EF, Travis SP; European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis. 2010;4(1):28-62. doi: 10.1016/j.crohns.2009.12.002.
  13. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on cortico-steroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130(3):940-87. doi: 10.1053/j.gas-tro.2006.01.048.
  14. Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, Moayyedi P. Glucocorti-costeroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):590-9; quiz 600. doi: 10.1038/ajg.2011.70.
  15. Baron JH, Connell AM, Kanaghinis TG, Len-nard-Jones JE, Jones AF. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J. 1962;2(5302):441-3.
  16. Ивашкин ВТ, Шелыгин ЮА, Абдулганиева ДИ, Абдулхаков РА, Алексеева ОП, Ачкасов СИ, Барановский АЮ, Белоусова ЕА, Головен-ко ОВ, Григорьев ЕГ, Костенко НВ, Лапина ТЛ, Маев ИВ, Москалев АИ, Низов АА, Николаева НН, Осипенко МФ, Павленко ВВ, Парфенов АИ, Полуэктова ЕА, Румянцев ВГ, Ти-мербулатов ВМ, Тертычный АС, Ткачев АВ, Трухманов АС, Халиф АЛ, Хубезов ДА, Чаш-кова ЕЮ, Шифрин ОС, Щукина ОБ. Рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктоло-гов России по диагностике и лечению взрослых больных язвенным колитом. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;25(1): 48-65.
  17. Российская гастроэнтерологическая ассоциация, Ассоциация колопроктологов России. Клинические рекомендации по диагностике и лечению взрослых пациентов с болезнью Крона. 2013. URL: http://www. gastro.ru/userfiles/Recom_BK.pdf.
  18. Gustavsson A, Halfvarson J, Magnuson A, Sandberg-Gertzen H, Tysk C, Jarnerot G. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am J Gastroenterol. 2007;102(11):2513-9. doi: 10.1111/j.1572-0241.2007.01435.x.
  19. Travis S, Satsangi J, Lemann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut. 2011;60(1):3-9. doi: 10.1136/gut.2010.216895.
  20. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF; European Crohn's and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443-68. doi: 10.1016/j.crohns.2013.12.013.
  21. Landolfo S, Gariglio M, Gribaudo G, Lembo D. The human cytomegalovirus. Pharmacol Ther. 2003;98(3):269-97. doi: http://dx.doi.org/10.1016/S0163-7258(03)00034-2.
  22. Nguyen M, Bradford K, Zhang X, Shih DQ. Cy-tomegalovirus reactivation in ulcerative colitis patients. Ulcers. 2011;2011. pii: 282507. doi: 10.1155/2011/282507.
  23. Kim JJ, Simpson N, Klipfel N, Debose R, Barr N, Laine L. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010;55(4):1059-65. doi: 10.1007/s10620-010-1126-4.
  24. Kim YS, Kim YH, Kim JS, Cheon JH, Ye BD, Jung SA, Park YS, Choi CH, Jang BI, Han DS, Yang SK, Kim WH; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. J Clin Gastroenterol. 2012;46(1):51-6. doi: 10.1097/MCG.0b013e3182160c9c.
  25. Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, Emmons J, Bajaj JS, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):345-51. doi: 10.1016/j.cgh.2006.12.028.
  26. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30(3):253-64. doi: 10.1111/j.1365-2036.2009.04037.x.
  27. Aberra FN, Stettler N, Brensinger C, Lichten-stein GR, Lewis JD. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2007;5(9):1070-5. doi: 10.1016/j.cgh.2007.04.007.
  28. Gan SI, Beck PL. A new look at toxic megaco-lon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol. 2003;98(11):2363-71. doi: 10.1111/j.1572-0241.2003.07696.x.
  29. Gerna G, Lilleri D. Monitoring transplant patients for human cytomegalovirus: Diagnostic update. Herpes. 2006;13(1):4-11.
  30. Roblin X, Pillet S, Oussalah A, Berthelot P, Del Tedesco E, Phelip JM, Chambonniere ML, Garraud O, Peyrin-Biroulet L, Pozzetto B. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppres-sive therapy in ulcerative colitis. Am J Gastroenterol. 2011;106(11):2001-8. doi: 10.1038/ajg.2011.202.
  31. Van Assche G, D'Haens G, Noman M, Ver-meire S, Hiele M, Asnong K, Arts J, D'Hoo-re A, Penninckx F, Rutgeerts P. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125(4):1025-31. doi: http://dx.doi.org/10.1016/S0016-5085(03)01214-9.
  32. Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Na-chury M, Moreau J, Delchier JC, Cosnes J, Ri-cart E, Dewit O, Lopez-Sanroman A, Dupas JL, Carbonnel F, Bommelaer G, Coffin B, Roblin X, Van Assche G, Esteve M, Farkkila M, Gis-bert JP, Marteau P, Nahon S, de Vos M, Fran-chimont D, Mary JY, Colombel JF, Lemann M; Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcer-ative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857):1909-15. doi: 10.1016/S0140-6736(12)61084-8.
  33. Sartelli M, Malangoni MA, Abu-Zidan FM, Griffiths EA, Di Bella S, McFarland LV, Eltringham I, Shelat VG, Velmahos GC, Kelly CP, Khanna S, Abdelsattar ZM, Alrahmani L, Ansaloni L, Au-gustin G, Bala M, Barbut F, Ben-Ishay O, Bhan-gu A, Biffl WL, Brecher SM, Camacho-Ortiz A, Cainzos MA, Canterbury LA, Catena F, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Co-cuz ME, Coimbra R, Cook CH, Cui Y, Czepiel J, Das K, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckert C, Eckmann C, Eiland EH, Enani MA, Faro M, Ferrada P, Forrester JD, Fraga GP, Frossard JL, Galeiras R, Ghnnam W, Gomes CA, Gorrepati V, Ahmed MH, Herzog T, Humphrey F, Kim JI, Isik A, Ivatury R, Lee YY, Juang P, Furuya-Kanamori L, Karamarkovic A, Kim PK, Kluger Y, Ko WC, LaBarbera FD, Lee JG, Leppaniemi A, Lohsiriwat V, Marwah S, Mazus-ki JE, Metan G, Moore EE, Moore FA, Nord CE, Ordonez CA, Junior GA, Petrosillo N, Porte-la F, Puri BK, Ray A, Raza M, Rems M, Sakaku-shev BE, Sganga G, Spigaglia P, Stewart DB, Tattevin P, Timsit JF, To KB, Trana C, Uhl W, Urbanek L, van Goor H, Vassallo A, Zahar JR, Caproli E, Viale P. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg. 2015;10:38. doi: 10.1186/s13017-015-0033-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Kharitonov A.G., Shchukina O.B., Kondrashina E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies